An Open-Label, Multi-Center, Phase 2 Study of Denosumab in Subjects With Giant Cell Tumor of Bone

Trial Profile

An Open-Label, Multi-Center, Phase 2 Study of Denosumab in Subjects With Giant Cell Tumor of Bone

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Nov 2017

At a glance

  • Drugs Denosumab (Primary)
  • Indications Bone cancer; Giant cell tumours
  • Focus Adverse reactions
  • Sponsors Amgen
  • Most Recent Events

    • 23 Nov 2017 Planned End Date changed from 3 Nov 2017 to 15 May 2018.
    • 23 Nov 2017 Planned primary completion date changed from 3 Nov 2017 to 15 May 2018.
    • 22 Nov 2017 This study has been completed in Austria
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top